Evidence map›Paper›PMID 38405793›Full record

ArticlebioRxiv : the preprint server for biology2024

Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson Syndrome and Toxic epidermal necrolysis.

Andrew Gibson, Ramesh Ram, Rama Gangula, Yueran Li, Eric Mukherjee, Amy M Palubinsky, Chelsea N Campbell, Michael Thorne, Katherine C Konvinse, Phuti Choshi and 13 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 3 countries.

Andrew GibsonInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Ramesh RamInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Rama GangulaDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Yueran LiInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Eric MukherjeeDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Amy M PalubinskyDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Chelsea N CampbellDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Michael ThorneInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Katherine C KonvinseDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Phuti ChoshiAllergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
Pooja DeshpandeInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Sarah PedrettiAllergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
Richard T O'NeilDepartment of Veterans Affairs, Ralph H Johnson VA Medical Center and Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
Celestine N WanjallaDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Spyros A KalamsDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Silvana GaudieriInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Rannakoe J LehloenyaAllergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
Samuel S BailinDepartment of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.
Abha ChopraInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Jason A Trubiano on behalf of the AUS-SCAR study group
Jonny G Peter on behalf of the AFRI-SCAR and IMARI-Africa study group
Simon A MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Elizabeth J PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, Australia.
Murdoch University · AUVanderbilt University Medical Center · USUniversity of Cape Town · ZAPeter Doherty Institute · AURalph H. Johnson VA Medical Center · US

Funding

Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0M
Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
UCSD PRIDE Faculty Development Program in Cardiovascular SciencesR25HL145817 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Robert Scott Ross, Joann Trejo · 2019 to 2026
$3.3M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
HIV-associated Tuberculosis Training Program (HATTP)D43TW010559 · FIC · UNIVERSITY OF CAPE TOWN · PI Graeme Ayton Meintjes · 2017 to 2026
$3.0M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435k
Blocking lung cancer progression with peptide delivering cell therapy platformsIK2BX004585 · VA · VETERANS HEALTH ADMINISTRATION · PI O'NEIL, RICHARD THOMAS · 2019 to 2023
–
BLRD VA IK2 BX004585FIC NIH HHS D43 TW010559NHGRI NIH HHS R01 HG010863NHLBI NIH HHS R25 HL145817NHLBI NIH HHS T32 HL007444NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI152183NIAID NIH HHS R21 AI139021NIAID NIH HHS U01 AI154659NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is a rare but life-threatening cutaneous drug reaction mediated by human leukocyte antigen (HLA) class I-restricted CD8+ T-cells. To obtain an unbiased assessment of SJS/TEN cellular immunopathogenesis, we performed single-cell (sc) transcriptome, surface proteome, and TCR sequencing on unaffected skin, affected skin, and blister fluid from 17 SJS/TEN patients. From 119,784 total cells, we identified 16 scRNA-defined subsets, confirmed by subset-defining surface protein expression. Keratinocytes upregulated HLA and IFN-response genes in the affected skin. Cytotoxic CD8+ T-cell subpopulations of expanded and unexpanded TCRαβ clonotypes were shared in affected skin and blister fluid but absent or unexpanded in SJS/TEN unaffected skin. SJS/TEN blister fluid is a rich reservoir of oligoclonal CD8+ T-cells with an effector phenotype driving SJS/TEN pathogenesis. This multiomic database will act as the basis to define antigen-reactivity, HLA restriction, and signatures of drug-antigen-reactive T-cell clonotypes at a tissue level.

Identifiers

PMID38405793
PMCPMC10888802
OpenAlexW4389041077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.